ERB-196 (WAY-202196)
(Synonyms: WAY-202196) 目录号 : GC30650
ERB-196 (WAY-202196) 是一种非甾体选择性雌激素受体-β； (ERβ) 激动剂。
Cas No.:550997-55-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist.
ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist. ERB-196 significantly reduces histopathologic evidence of injury to the gastrointestinal mucosal surface (0.7±0.1 vs. 2.3±0.2 for control; p<0.05). The mucosal mass of 10-cm segments of small bowel mucosa shows better preservation of mucosal mass than control treatment (63±20 [ERB-196] vs. 31±24 [control]), but this difference fails to reach statistical significance (p<0.06). The administration of ERB-196 is highly effective in the prevention of lethality. Consistent with the neutropenic rat model, ERB-196 significantly increases survival when compare with vehicle control[1].
[1]. Cristofaro PA, et al. WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med. 2006 Aug;34(8):2188-93.
Animal experiment: | The neutropenic rat model of pseudomonas sepsis are used in this study. For the survival study, ERB-196 (50 mg/kg; n=12) or vehicle control (n=8) is administered daily by orogastric feeding beginning on day 4 after the first dose of cyclophosphamide and continuing for 8 days. Animals are assessed clinically and pathologically by measuring daily body weight, body temperature, presence of bacteremia, circulating endotoxin levels, and pathologic evidence of damage to the gastrointestinal epithelium and liver by light microscopy and electron microscopy. Blood and tissue samples are serially diluted in sterile saline and incubated at 37°C on pseudomonas agar for quantitative assessment of bacterial concentrations[1]. |
References: [1]. Cristofaro PA, et al. WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med. 2006 Aug;34(8):2188-93. | |
| Cas No. | 550997-55-2 | SDF | |
| 别名 | WAY-202196 | ||
| Canonical SMILES | N#CC1=C2C=C(O)C=CC2=CC(C3=CC=C(O)C(F)=C3)=C1 | ||
| 分子式 | C17H10FNO2 | 分子量 | 279.27 |
| 溶解度 | Ethanol : 16 mg/mL (57.29 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5808 mL | 17.9038 mL | 35.8076 mL |
| 5 mM | 0.7162 mL | 3.5808 mL | 7.1615 mL |
| 10 mM | 0.3581 mL | 1.7904 mL | 3.5808 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet